BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 12175689)

  • 1. Combination of taxanes and anthracyclines in first-line chemotherapy of metastatic breast cancer: an interim report.
    Friedrichs K; Hölzel F; Jänicke F
    Eur J Cancer; 2002 Sep; 38(13):1730-8. PubMed ID: 12175689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Taxanes in the first-line chemotherapy of metastatic breast cancer: review.
    Friedrich M; Diesing D; Villena-Heinsen C; Felberbaum R; Kolberg HC; Diedrich K
    Eur J Gynaecol Oncol; 2004; 25(1):66-70. PubMed ID: 15053065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docetaxel-anthracycline combinations in metastatic breast cancer.
    Nabholtz JM
    Breast Cancer Res Treat; 2003; 79 Suppl 1():S3-9. PubMed ID: 12868800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Compilation of phase I and II trial data of docetaxel and doxorubicin in the treatment of advanced breast cancer and other malignancies.
    Sparano JA
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):10-5. PubMed ID: 9865686
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
    Ravdin PM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combining new agents with anthracyclines in metastatic breast cancer: an overview of recent findings.
    Aapro MS
    Semin Oncol; 1999 Feb; 26(1 Suppl 3):17-21. PubMed ID: 10203266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The choice of adjuvant combination therapies with taxanes: rationale and issues addressed in ongoing studies.
    Nabholtz JM; Riva A
    Clin Breast Cancer; 2001 Oct; 2 Suppl 1():S7-14. PubMed ID: 11970739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimal sequence of anthracyclines and taxanes as adjuvant breast cancer treatment.
    Vici P; Viola G; Rossi S; Botti C; Vitucci C; Sergi D; Ferranti FR; Saracca E; Di Lauro L; Corsetti S; Foggi P; Fattoruso SI; Lopez M
    Clin Ter; 2008; 159(6):453-6. PubMed ID: 19169608
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Taxanes for breast cancer: an evidence-based review of randomized phase II and phase III trials.
    Sparano JA
    Clin Breast Cancer; 2000 Apr; 1(1):32-40; discussion 41-2. PubMed ID: 11899388
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment for anthracycline-pretreated metastatic breast cancer.
    O'Shaughnessy J; Twelves C; Aapro M
    Oncologist; 2002; 7 Suppl 6():4-12. PubMed ID: 12454314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer.
    Piccart-Gebhart MJ; Burzykowski T; Buyse M; Sledge G; Carmichael J; Lück HJ; Mackey JR; Nabholtz JM; Paridaens R; Biganzoli L; Jassem J; Bontenbal M; Bonneterre J; Chan S; Basaran GA; Therasse P
    J Clin Oncol; 2008 Apr; 26(12):1980-6. PubMed ID: 18421049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of docetaxel (Taxotere) in neoadjuvant chemotherapy of breast cancer.
    Costa SD; von Minckwitz G; Raab G; Blohmer JU; Dresel V; Eidtmann H; Hilfrich J; Jackisch C; Merkle E; Gademann G; Kaufmann M
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):24-31. PubMed ID: 10426456
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin in combination with the taxanes.
    Trudeau M; Pagani O
    Semin Oncol; 2001 Aug; 28(4 Suppl 12):41-50. PubMed ID: 11552229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The current status of docetaxel for metastatic breast cancer.
    Esteva FJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Docetaxel and anthracycline polychemotherapy in the treatment of breast cancer.
    Nabholtz JM; Smylie M; Mackey J; Au HJ; Tonkin K; Au R; Morrish D; Salter E
    Semin Oncol; 1999 Jun; 26(3 Suppl 8):47-52. PubMed ID: 10403474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospects with docetaxel in the treatment of patients with breast cancer.
    Marty M; Extra JM; Cottu PH; Espié M
    Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of breast cancer: are the taxanes going to change the natural history of breast cancer?
    Nabholtz JM; Tonkin K; Smylie M; Au HJ; Lindsay MA; Mackey J
    Expert Opin Pharmacother; 2000 Jan; 1(2):187-206. PubMed ID: 11249542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [New combination chemotherapies for breast cancer].
    Aiba K
    Gan To Kagaku Ryoho; 2000 Mar; 27(3):362-74. PubMed ID: 10740629
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction between Herceptin and taxanes.
    Diéras V; Beuzeboc P; Laurence V; Pierga JY; Pouillart P
    Oncology; 2001; 61 Suppl 2():43-9. PubMed ID: 11694787
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risks and benefits of taxanes in breast and ovarian cancer.
    Michaud LB; Valero V; Hortobagyi G
    Drug Saf; 2000 Nov; 23(5):401-28. PubMed ID: 11085347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.